Consensus Exelixis, Inc.

Stocks

EXEL

US30161Q1040

Biotechnology & Medical Research

Market Closed - Nasdaq 06:00:00 05/09/26 am AEST			5-day change	1st Jan Change
59.01 ^USD	-0.20%		+8.00%	+34.63%

01/09	Exelixis Wins Appeal in Patent Case Against MSN Laboratories	MT
06/08	Exelixis, Inc., Q2 2026 Earnings Call, Aug 05, 2026

Evolution of the Average Target: Exelixis, Inc.

Evolution of the Target Price: Exelixis, Inc.

Changes in Analyst Recommendations: Exelixis, Inc.

7446e34431c886f74f8a9b2.9scLckzr8JmwA8VnwYb5m4n-3y6L1E8VDej_yn7a8bE.nvBUFH6vsd_mbL9Viu6R9sqzthjlnhZ4Za-3-yywktzFr3w5fIDA1-d2lA~108bfe8f1ebf8e36677173fda64fea16

Analysts' recommendations: Exelixis, Inc.

23/07	Analyst recommendations: Duke Energy, JPMorgan Chase, M&T Bank, Super Micro, Texas Instruments…
13/07	Analyst recommendations: Biogen, Deckers Outdoor, Fortinet, Marathon Petroleum, UnitedHealth…
07/07	RBC Capital Adjusts Exelixis Price Target to $46 From $43, Maintains Sector Perform Rating	MT
03/07	Exelixis Faces Balanced Risk-Reward Ahead of Key Catalysts, UBS Says	MT
03/07	UBS Adjusts Price Target on Exelixis to $52 From $43, Maintains Neutral Rating	MT
02/07	Analyst recommendations: Adobe, AA, Nike, Exelixis…
07/05	Exelixis Seen Trading Steady on Modest Drug Growth, RBC Says	MT
03/03	RBC Lowers Price Target on Exelixis to $43 From $46, Keeps Sector Perform Rating	MT
12/02	RBC Raises Price Target on Exelixis to $46 From $45, Keeps Sector Perform Rating	MT
02/02	Morgan Stanley Lifts Price Target on Exelixis to $49 From $48, Keeps Overweight Rating	MT
15/01	Truist Securities Adjusts Price Target on Exelixis to $51 From $49, Maintains Buy Rating	MT
09/01	Exelixis Shares Fall After Downgrade From Morgan Stanley	MT
08/01	Morgan Stanley Downgrades Exelixis to Equalweight, Price Target is $48	MT
06/01	Exelixis Faces Limited High-Impact Catalysts, BofA Says	MT
06/01	BofA Securities Downgrades Exelixis to Underperform From Neutral, Adjusts Price Target to $41 From $43	MT
07/11	UBS Adjusts Price Target on Exelixis to $40 From $35, Maintains Neutral Rating	MT
05/11	Morgan Stanley Lifts Price Target on Exelixis to $45 From $44, Keeps Overweight Rating	MT
04/11	Exelixis Shares Fall After Guggenheim Downgrade	MT
03/11	Guggenheim Downgrades Exelixis to Neutral From Buy	MT
22/10/25	Exelixis Shares Rise After Leerink Partners Upgrade	MT
21/10/25	Leerink Partners Upgrades Exelixis to Outperform From Market Perform, Adjusts Price Target to $48 From $38	MT
18/10/25	Exelixis, Inc. Announces Results from Subgroup Analysis of CABINET Phase 3 Pivotal Trial Evaluating Cabozantinib in Advanced Lung and Thymic Neuroendocrine Tumors at ESMO 2025	CI
31/07/25	UBS Adjusts Price Target on Exelixis to $38 From $43, Maintains Neutral Rating	MT
29/07/25	Analyst recommendations: Blackstone, Airbnb, Amphenol, Cadence Design Systems, Ameriprise Financial...
29/07/25	RBC Lowers Price Target on Exelixis to $45 From $50, Keeps Sector Perform Rating	MT

More recommendations

Bio Therapeutic Drugs

	Add to a list 0 selected To use this feature you must be a member Log in Sign up	Consensus	Analysts' recommendations evolution (4 months)	Financial estimates divergence	Analysts' Target price divergence	Objective/dr gap
	EXELIXIS, INC.					-9.02%
	WUXI APPTEC CO., LTD.					+21.09%
	ARGENX SE					+11.95%
	INSMED INCORPORATED					+58.51%
	BIONTECH SE					+15.94%
	WUXI BIOLOGICS (CAYMAN) INC.					+16.61%
	GENMAB A/S					+12.11%
	PHARMAESSENTIA CORPORATION					+6.66%
	SICHUAN KELUN-BIOTECH BIOPHARMACEUTICAL CO., LTD.					+26.36%
	SUMMIT THERAPEUTICS INC.					+61.47%
	Average					+22.17%
	Weighted average by Cap.					+20.98%